title: [A retrospective study of carboplatin and weekly paclitaxel combination chemotherapy for elderly patients with advanced non-small cell lung cancer].
abstract: OBJECTIVE
  To perform a retrospective analysis of carboplatin (CBDCA) and weekly paclitaxel (PTX) combination chemotherapy for elderly patients with unresectable non-small cell lung cancer (NSCLC) in order to evaluate both treatment efficacy and toxicity.
  
  
  METHODS
  48 patients aged more than 70 years with non-resectable NSCLC who received CBDCA+weekly PTX from January 2001 to March 2008.
  
  
  RESULTS
  The median age of the patients (32 male, 16 female) was 74 years. Patients received 1-6 courses of this chemotherapy (median 4 courses). The overall response rate, time to progression, median survival time and 1-year survival rate was 51%, 183 days, 411 days and 52%, respectively. With regard to toxicity, grade 3-4 neutropenia was observed in 38% of patients and anemia in 25% of the patients, and 29% of the patients had grade 2 and above periferal nerve disorder.
  
  
  CONCLUSIONS
  This regimen showed a good response and was safe for elderly patients with advanced NSCLC, but a high incidence of neuropathy was observed.
authors.affiliation: Dept. of Respiratory Disease, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Mito
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ohashi
authors.forename: Toshiki
authors.initials: T
authors.lastname: Kajihara
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nitta
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Awaya
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Ikegami
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Arita
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D016190:Carboplatin; D017239:Paclitaxel